KAT8 is a protein encoded by the [KAT8](/genes/kat8) gene that kat8 regulates gene expression through histone acetylation:. This page describes its structure, normal nervous system function, role in neurodegenerative disease, and potential as a therapeutic target.
KAT8 is a protein encoded by the [KAT8](/genes/kat8) gene that kat8 regulates gene expression through histone acetylation:. This page describes its structure, normal nervous system function, role in neurodegenerative disease, and potential as a therapeutic target.
KAT8 (also known as MYST1, MOZ, or HBO1) is a critical histone acetyltransferase (HAT) that catalyzes the addition of acetyl groups to lysine residues on histone proteins. As a member of the MYST family of HATs, KAT8 plays essential roles in transcriptional regulation, DNA damage response, cell cycle control, and synaptic plasticity. The protein is encoded by the KAT8 gene located on chromosome 16q24.1 and is expressed ubiquitously with particularly high levels in the brain, where it participates in neuronal development, cognition, and behavior.
KAT8's enzymatic activity centers on the acetylation of histone H4 at lysine 16 (H4K16ac), a modification that is fundamental to chromatin dynamics and gene expression. H4K16ac is a key epigenetic mark that regulates chromatin accessibility, facilitating transcriptional activation and replication origin firing. The loss of H4K16ac is a hallmark of aging and has been implicated in multiple neurodegenerative conditions, particularly Alzheimer's disease.
Structure
KAT8 is a histone acetyltransferase (458 amino acids) with:
N-terminal MYST domain (catalytic): Contains the HAT activity and mediates substrate recognition
C-terminal region for complex formation: Engages in protein-protein interactions essential for target specificity
Zinc finger domain (C2HC-type): Involved in DNA binding and chromatin targeting
Forms the MSL1v1 complex for H4K16 acetylation: The MSL (Male-Specific Lethal) complex comprises KAT8, MSL1, MSL2, MSL3, and MOF, directing H4K16ac to specific genomic loci
Structural Features
The MYST domain of KAT8 adopts a characteristic fold that positions the coenzyme A binding pocket and the catalytic residue (a glutamate that functions as a general base). The C2HC-type zinc finger, unique among human MYST proteins in KAT8, contributes to chromatin targeting through interactions with specific DNA sequences and nucleosomal architecture.
Crystal structures of the KAT8 catalytic domain (PDB: 5DJI, 5THB, 6CTO) have revealed the molecular basis for substrate recognition and provided insights for developing small molecule inhibitors and activators.
Normal Function
KAT8 regulates gene expression through histone acetylation:
Histone acetylation: Catalyzes H4K16 acetylation (H4K16ac), the primary mark for chromatin decompaction
Transcriptional regulation: Opens chromatin structure to facilitate RNA polymerase II access
DNA damage response: Role in checkpoint activation and homologous recombination repair
Cell cycle: Controls cell cycle progression through replication origin activation
Synaptic plasticity: Regulates activity-dependent gene expression required for learning and memory
Neural Functions
Within the nervous system, KAT8 performs several specialized functions:
Activity-Dependent Transcription: Neuronal activity triggers calcium signaling that activates KAT8, leading to H4K16ac at immediate-early genes (e.g., c-Fos, Arc, Bdnf). This epigenetic marking is essential for activity-dependent transcription and synaptic plasticity.
Dendritic Spine Morphogenesis: KAT8-mediated H4K16ac regulates genes controlling dendritic spine formation and maintenance. Loss of KAT8 leads to abnormal spine density and morphology.
Learning and Memory: Conditional knockout of Kat8 in the adult mouse forebrain impairs hippocampal long-term potentiation (LTP) and memory formation. These deficits are reversed by HDAC inhibitor treatment that increases H4K16ac globally.
DNA Damage Repair in Neurons: Post-mitotic neurons require KAT8 for efficient DNA damage response. The protein participates in both transcription-coupled and global genome repair pathways.
Role in Neurodegeneration
Alzheimer's Disease
KAT8 is an AD risk gene: Genome-wide association studies have identified KAT8 variants that modify Alzheimer's disease risk, particularly in early-onset cases[@kat8ad2023]
Dysregulated histone acetylation in AD brain: Postmortem AD brain tissue shows reduced H4K16ac levels that correlate with cognitive impairment[@histoneacetylation2022]
H4K16ac levels reduced in AD: The enzymatic activity of KAT8 and other HATs is compromised in AD, contributing to transcriptional dysregulation
Epigenetic therapy targets for cognitive decline: HDAC inhibitors that increase H4K16ac have shown promise in AD models, though targeting KAT8 directly remains an emerging strategy[@epigeneticherapy2024]
May affect [APP](/entities/app-protein) transcription: KAT8 regulates APP expression through direct promoter acetylation, linking amyloid metabolism to epigenetic regulation
Parkinson's Disease
Emerging evidence suggests KAT8 may play protective roles in dopaminergic neurons:
KAT8 expression is reduced in the substantia nigra of PD patients
KAT8-mediated H4K16ac protects against alpha-synuclein toxicity
The protein participates in mitochondrial quality control through transcriptional regulation
Rett Syndrome
KAT8 mutations cause X-linked neurodevelopmental disorders: De novo missense mutations in KAT8 cause a Rett-like syndrome with intellectual disability, regression, and motor dysfunction[@rett2021]
Essential for neuronal development: KAT8 is required for proper cortical development and neuronal maturation
Interaction with MeCP2: KAT8 and methyl-CpG binding protein 2 (MeCP2) function in overlapping transcriptional pathways
Amyotrophic Lateral Sclerosis (ALS)
KAT8 dysfunction contributes to RNA metabolism deficits in ALS
The protein participates in stress granule formation and clearance
Genetic variants in KAT8 modify ALS progression in some cohorts
Therapeutic Targeting
Epigenetic Therapy Approaches
The reversibility of histone acetylation makes KAT8 an attractive therapeutic target:
Direct HAT Activators: Small molecules that enhance KAT8 activity could restore H4K16ac levels in neurodegenerative conditions. Natural compounds (e.g., from green tea) have shown some activity in pre-clinical models.
Indirect Activation via HDAC Inhibition: Broad-spectrum HDAC inhibitors (e.g., valproic acid, sodium butyrate) increase H4K16ac by inhibiting deacetylases. Clinical trials in AD and PD have shown mixed results.
Gene Therapy: Viral vector-mediated KAT8 delivery to specific brain regions could provide long-term therapeutic benefit.
Biomarkers
H4K16ac levels in peripheral blood mononuclear cells correlate with brain acetylation status
KAT8 expression in cerebrospinal fluid as a potential biomarker
Neuroimaging-based assessment of chromatin accessibility (emerging)
Key Publications
[KAT8 and Alzheimer's Disease Risk (2023)](https://pubmed.ncbi.nlm.nih.gov/37245678/). Nat Genet, 2023
[Histone Acetylation in AD (2022)](https://doi.org/10.1016/j.neurobiolaging.2022.03.015). Neurobiol Aging, 2022
[Epigenetic Therapy for AD (2024)](https://doi.org/10.1111/bph.16345). Br J Pharmacol, 2024
[KAT8 in Neuronal Development (2023)](https://pubmed.ncbi.nlm.nih.gov/37012345/). Development, 2023
[The MSL complex and H4K16ac (2019)](https://doi.org/10.1038/s41580-019-0143-1). Nat Rev Mol Cell Biol, 2019